Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D-ACE2 CAR-NK Cells for COVID-19
NCT04324996Phase 2Unknown
- Sponsor
- Chongqing Public Health Medical Treatment Center
- Start
- Feb 2020
- Primary completion
- Feb 2022
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of NKG2D-ACE2 CAR-NK Cell in coronavirus disease 2019 (COVID-19), sponsored by Chongqing Public Health Medical Treatment Center. Status: unknown.
02
Drugs
NKG2D-ACE2 CAR-NK Cell
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04324996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324996.